KemPharm, Inc. (NASDAQ:KMPH) has earned an average rating of “Buy” from the six brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $9.25.
A number of brokerages have issued reports on KMPH. Zacks Investment Research lowered KemPharm from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Royal Bank of Canada set a $9.00 price target on KemPharm and gave the stock a “buy” rating in a research note on Tuesday. Finally, ValuEngine upgraded KemPharm from a “strong sell” rating to a “sell” rating in a research note on Monday, October 23rd.
Shares of KemPharm (NASDAQ KMPH) opened at $5.64 on Friday. KemPharm has a 12 month low of $2.45 and a 12 month high of $5.75. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of -1.92. The stock has a market capitalization of $82.08 and a price-to-earnings ratio of -1.93.
In other news, EVP Daniel L. Cohen acquired 7,500 shares of the business’s stock in a transaction dated Monday, November 27th. The stock was purchased at an average price of $3.79 per share, for a total transaction of $28,425.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 22.80% of the company’s stock.
An institutional investor recently raised its position in KemPharm stock. C WorldWide Group Holding A S grew its position in shares of KemPharm, Inc. (NASDAQ:KMPH) by 14.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 435,528 shares of the specialty pharmaceutical company’s stock after purchasing an additional 53,829 shares during the period. C WorldWide Group Holding A S owned approximately 2.97% of KemPharm worth $1,611,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 36.04% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.